

# UC Davis

## UC Davis Previously Published Works

### Title

Choriovitreous Neovascularization After Resolution of Infectious Chorioretinitis.

### Permalink

<https://escholarship.org/uc/item/3937d2qb>

### Journal

Retina, 39(6)

### ISSN

0275-004X

### Authors

Mukkamala, Lekha

Yiu, Glenn

### Publication Date

2019-06-01

### DOI

10.1097/iae.0000000000002558

Peer reviewed



Published in final edited form as:

Retina. 2019 June ; 39(6): e21–e22. doi:10.1097/IAE.0000000000002558.

## Choriovitreous Neovascularization following resolution of Infectious Chorioretinitis

Lekha Mukkamala, MD<sup>1</sup> and Glenn Yiu, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA 95817

### Summary statement:

This report describes the first documented case of choriovitreous neovascularization (CVNV) occurring after infectious chorioretinitis, with OCT-angiography (OCT-A) demonstrating flow through the vitreal portion of the lesion, and response to anti-VEGF therapy.

### Keywords

Choriovitreous neovascularization; optical coherence tomography angiography; OCT angiography; choroidal neovascular membrane; infectious chorioretinitis

Choriovitreous neovascularization (CVNV) is a rare condition where choroidal neovascularization (CNV) extends into the vitreous cavity. Although sporadic cases have been reported,<sup>1, 2</sup> CVNV often occurs as a result of iatrogenic damage to the retinal layers and Bruch's membrane from high-energy laser or cryotherapy<sup>3</sup> for treating various pathologies such as diabetic retinopathy, sickle cell disease,<sup>4</sup> retinal vein occlusions,<sup>3</sup> and tumors.<sup>5</sup> Prior reports of CVNV preceded the widespread use of anti-vascular endothelial growth factor (anti-VEGF) agents, and were associated with a poor prognosis.

A 56-year-old man with methicillin-sensitive *S. aureus* (MSSA) bacteremia and endocarditis presented with vitritis and focal chorioretinitis temporal to the fovea, which appeared as a hyperreflective lesion on OCT (Figure 1A). A week after systemic penicillin treatment, OCT showed resolution of the chorioretinitis lesion with focal loss of most retinal layers and Bruch's membrane (Figure 1B). Two weeks later, a choroidal neovascular membrane (CNV) developed at the site of the prior lesion, which appear similar to the retinal infiltrate on OCT (Figure 1C), but was distinguished by the presence of hemorrhage on clinical exam. Monthly intravitreal bevacizumab led to improvement in the retinal hemorrhage, but persistence of the CNV. After adjunct treatment with half-fluence photodynamic therapy (PDT), the CNV decreased in size, but extended into the vitreous cavity along the posterior hyaloid (Figure 1D). OCT angiography (OCT-A) revealed vascular flow (red areas, Figure 2A) through both the base of the lesion in the avascular outer retinal slab (purple dashed lines, Figure 2A), and the apex of the lesion along the vitreoretinal interface (yellow dashed lines, Figure 2A),

Contact Information: Glenn Yiu, MD, PhD, UC Davis Health System, 4860 Y St., Suite 2400, Sacramento, CA 95817, (916) 734-6602, gyiu@ucdavis.edu.


The authors have no proprietary interest in the subject of this manuscript.

consistent with CVNV. The en face OCT-A images corresponding to these segmented slabs demonstrate the CVNV architecture at different layers (Figures 2B and 2C). Further treatment with bevacizumab resulted in decreased flow through the CVNV lesion, although the overall structure appeared overall unchanged (not shown).

This unique case demonstrates a CVNV lesion that developed through a full-thickness defect in the retina and Bruch's membrane caused by infectious chorioretinitis, with reduction of vascular flow on OCT-A in response to anti-VEGF treatment. The lesion developed after switching to PDT therapy, suggesting that anti-VEGF therapy may be more effective than PDT in suppressing CVNV. OCT-A may be helpful in diagnosing this condition and monitoring clinical response to therapy.


## References:

1. Sinclair SH, Salmenson BD. Idiopathic choriovitreal membrane—a case report. *Br J Ophthalmol* 1992;76:567–8. [PubMed: 1384691]
2. Lee SY, Kwon YH, Chung H, et al. Clinical and OCT features in spontaneously progressive idiopathic choriovitreal neovascularization. *Ophthalmic Surg Lasers Imaging* 2007;38(2):151–3. [PubMed: 17396697]
3. Lim J Iatrogenic choroidal neovascularization. *Surv Ophthalmol* 1999;44(2):95–111. [PubMed: 10541149]
4. Acheson RW, Fox PD, Chuang EL, Serjeant GR. Treatment of iatrogenic choriovitreal neovascularization in sickle cell disease. *Br J Ophthalmol* 1991;75:729–30. [PubMed: 1722704]
5. Kiratli H, B. S Choriovitreal neovascularization following transpupillary thermotherapy for choroidal melanoma. *Eye (Lond)* 2003;17(3):436–7.



**Figure 1. Progression of chorioretinitis to choriovitreal neovascularization (CVNV)**

Optical coherence tomography (OCT) B-scans demonstrating focal chorioretinitis at presentation (A) and its resolution one week after systemic treatment, leaving a defect in most of the retinal layers and Bruch's membrane (B). A choroidal neovascular membrane developed 2 weeks later (C), with the CVNV forming 6 weeks after photodynamic therapy (D).



**Figure 2. Optical coherence tomography angiography (OCT-A) of choriovitreal neovascularization (CVNV)**

OCT-A B-scan through CVNV lesion (A), demonstrating vascular flow (red). Purple dotted lines show segmentation of the avascular layer with flow in the base of the lesion, which corresponds to the en-face projections (B). Yellow dotted lines highlight segmentation of vitreoretinal interface with flow in the apex of the lesion seen on en-face projections (C).